- Conditions
- Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
- Interventions
- patisiran
- Drug
- Lead sponsor
- Austin Neuromuscular Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,146
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wilson Disease
- Interventions
- Not listed
- Lead sponsor
- Prime Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Sacramento, California • New Haven, Connecticut + 4 more
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Frameshift Array blood sample test
- Genetic
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Day to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas
- Conditions
- Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders, Circadian Dysregulation
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 20 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Tafamidis
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Interventions
- Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,667 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, RFC1 Gene Mutation, Spinocerebellar Ataxia Type 27b, Healthy Participants
- Interventions
- Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, Assessments and Questionnaires, Cerebrospinal Fluid Collection
- Genetic · Other
- Lead sponsor
- Lauren Moore
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2030
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Gainesville, Florida + 12 more
- Conditions
- Huntington's Disease
- Interventions
- Pridopidine
- Drug
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Myopathy, Muscular Dystrophies, Myositis, Myofibrillar Myopathy, Congenital Myopathy, Distal Myopathy, Myopathies
- Interventions
- Electrical Impedance Myography
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Huntington Disease
- Interventions
- Not listed
- Lead sponsor
- Huntington Study Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
- Interventions
- GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder, ADHD
- Interventions
- Anger control training
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 11 Years to 16 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Spinal Muscular Atrophy 1
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Arthritis, Osteoarthritis
- Interventions
- tanezumab, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 697 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 82
- States / cities
- Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more
- Conditions
- Familial Dysautonomia
- Interventions
- Kinetin
- Dietary Supplement
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
- Interventions
- BFB-101 (AAV9-CBh-AP4B1)
- Biological
- Lead sponsor
- BlackfinBio Ltd
- Industry
- Eligibility
- 12 Months to 60 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Juvenile Neuronal Ceroid Lipofuscinosis
- Interventions
- Mycophenolate mofetil, Liquid Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Vibegron
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Interventions
- alpelisib
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 34
- States / cities
- Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- OAV101
- Genetic
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Norfolk, Virginia • Madison, Wisconsin
- Conditions
- Hereditary Amyloidosis, Transthyretin-Related
- Interventions
- neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
- Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania